#United States #New York #Pomerantz Law #ADC Therapeutics #ZYNLONTA

Investigation Surrounding ADC Therapeutics SA

The Pomerantz Law Firm has embarked on an investigation into ADC Therapeutics SA, a biotechnology firm traded on the NYSE under the ticker ADCT. The investigation centers on potential claims associated with possible securities fraud and other unlawful business practices involving the company and its management.

Background of ADC Therapeutics SA

ADC Therapeutics specializes in the development of anti-cancer therapeutics. Recently, the company announced its Phase 3 LOTIS-5 trial results concerning the efficacy of ZYNLONTA (loncastuximab tesirine-lpyl), a novel treatment for patients with relapsed or refractory diffuse large B-cell lymphoma. These results indicated a modest improvement in progression-free survival; however, they also revealed troubling data concerning patient mortality rates.

Recent Developments

On June 3, 2026, ADC disclosed its trial outcomes, showing a 1.4-month extension in progression-free survival for patients receiving ZYNLONTA combined with rituximab. Despite this, the treatment also presented alarming statistics: during the trial, there were 27 reported deaths among patients administered with ZYNLONTA, compared to only 9 in the control group receiving immunotherapy alone. This discrepancy raised red flags about the treatment's overall safety and efficacy.

In the wake of this announcement, ADC's stock price plummeted by $2.05, equating to a 66.56% drop over a span of two trading days, with shares closing at $1.03 on June 5, 2026. Such a sharp decline has prompted concern among investors about the potential for corporate misconduct and misrepresentation regarding the treatment's risks and benefits.

Purpose of the Investigation

Pomerantz LLP, a law firm renowned for its expertise in corporate and securities class litigation, is proactively ensuring that investors have the opportunity to pursue any claims resulting from these possible securities violations. The firm is reaching out to affected investors, urging them to connect with their attorneys for guidance. Danielle Peyton, a point of contact at Pomerantz, can be reached at [email protected] or by calling 646-581-9980, extension 7980.

The firm is committed to representing the rights of investors and the victims of securities fraud, underscoring its longstanding history of combating corporate misconduct. Founded by Abraham L. Pomerantz, a pioneer in class action law, the firm has garnered a reputation for effectively securing substantial settlements for its clients, further solidifying its authoritative presence in the industry.

What’s Next?

Investors affected by the recent developments at ADC Therapeutics are encouraged to participate in this investigation. With potential class action litigation on the horizon, they may have the opportunity to recover losses sustained due to the company's business practices or misleading statements.

The legal team at Pomerantz will work diligently to ensure any claims brought forward are addressed thoroughly, with a focus on seeking justice for those adversely impacted by ADC's actions.

In conclusion, the situation at ADC Therapeutics serves as a pertinent reminder of the volatility present in the biotech sector, where clinical trial outcomes can significantly affect stock performance. Investors are advised to stay vigilant and informed of their rights amidst such turbulent circumstances.